Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79890.090.062%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Aprea Therapeutics Inc

APRENASDAQ
Trade with Public
Trade with Public
$0.7943
-0.012-1.49%
At close: Sep 4, 5:00 PM EST
$0.8100
0.01571.98%
After Hours: Sep 4, 6:44 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Aprea Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aprea Therapeutics (APRE).

Price Target Range — 11 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingOutperform# Analysts3Avg. Consensus PT$3Upside to Avg. PT+279.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026WedbushRobert DriscollPT CutOutperform$6→$3
May 14, 2026WedbushRobert DriscollPT CutOutperform$7→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
Benzinga Newsdesk

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.
Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and lowers the price target from $4 to $1.2.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved